Zobrazeno 1 - 10
of 99
pro vyhledávání: ''
Autor:
Yucai Wang, Arushi Khurana, Thomas M. Habermann, Jose C. Villasboas, Brian K. Link, William R. Macon, Stephen M. Ansell, Matthew J. Maurer, Raphael Mwangi, James R. Cerhan, Rebecca L. King, Christopher Strouse, Grzegorz S. Nowakowski, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed it
Autor:
Jia-Ying Wu, Yi Xiao, Yicheng Zhang, Jianfeng Zhou, Fankai Meng, Yang Cao, Na Wang, Xiaojian Zhu, Jue Wang, Lifang Huang
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. He
Autor:
Florent Malard, Jean-Luc Harousseau, Ali Bazarbachi, Abdul Hamid Bazarbachi, Mohamad Mohty, Rama Al Hamed
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-13 (2021)
Blood Cancer Journal
Blood Cancer Journal, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
Blood Cancer Journal
Blood Cancer Journal, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
We conducted a prospective cohort study in newly diagnosed systemic light chain (AL) amyloidosis patients (N = 59) to study patient-reported outcomes (PROs) through the first year. The median age was 68 years with 42% female, 8% Black, and 78% lambda
Autor:
Luke Zheng, Vaishali Sanchorawala, Dina Brauneis, J. Mark Sloan, Shayna Sarosiek, Karen Quillen
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-6 (2020)
Blood Cancer Journal
Blood Cancer Journal
Hematologic complete response (hemCR) in AL amyloidosis requires absence of monoclonal protein by immunofixation electrophoreses (IFE) and normal serum free light chain ratio (FLCR). Recent literature suggests that an involved free light chain (iFLC)
Autor:
Maria Gavriatopoulou, Lia-Angela Moulopoulos, Evangelos Terpos, Nikolaos Kanellias, Andriani Βoultadaki, Efstathios Kastritis, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Charis Bourgioti, Despina Fotiou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Vassilis Koutoulidis
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 9, Pp 1-7 (2020)
Blood Cancer Journal
Blood Cancer Journal
Introduction: Multiple myeloma (MM) is the second most common haematological malignancy and is characterized by bone marrow infiltration of monoclonal plasma cells and end-organ involvement. Smoldering MM (SMM) is an intermediate clinical entity betw
Autor:
Bradley Heidrich, Yingzhe Li, Leopoldo Luistro, Mcdaid Ronan, Priyanka Nair-Gupta, Kathryn Packman, Francois Gaudet, Stephen I. Rudnick, Jocelin Joseph, Melissa Smith, Ricardo Attar, Kodandaram Pillarisetti
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 6, Pp 1-13 (2020)
Blood Cancer Journal
Blood Cancer Journal
Redirecting T cells to specifically kill malignant cells has been validated as an effective anti-cancer strategy in the clinic with the approval of blinatumomab for acute lymphoblastic leukemia. However, the immunosuppressive nature of the tumor micr
Autor:
Paul Cockwell, Nelson Leung, Paul W. Sanders, Insara Jaffer Sathick, Punit Yadav, Mark Cook, Elizabeth E. Brown
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-8 (2020)
Blood Cancer Journal
Blood Cancer Journal
Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The level of free light chain (FLC) that causes MCN varies substantially and there is uncertainty about the threshold level that should be used to i
Autor:
Hayley Suen, Gabriele De Rubis, Yiu Lam Kwan, Douglas E. Joshua, Sabna Rajeev Krishnan, Mary Bebawy
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-11 (2020)
Blood Cancer Journal
Blood Cancer Journal
Multiple myeloma is an incurable cancer of bone marrow plasma cells, with a 5-year survival rate of 43%. Its incidence has increased by 126% since 1990. Treatment typically involves high-dose combination chemotherapy, but therapeutic response and pat
Autor:
Catherine R. Marinac, Brenda M. Birmann, Jenny Soiffer, Irene M. Ghobrial, Timothy R. Rebbeck
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 2, Pp 1-8 (2020)
Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smolde